Spectral MD, a Delaware company based in Dallas, Texas, is a predictive analytics company that develops proprietary AI algorithms and optical technology for faster treatment decisions in wound care. The company has started trading on AIM after raising £11.3m by way of an oversubscribed placing of new common stock.
A Reed Smith team based in London and New York advised Spectral MD on the transaction, with the UK team advising on all aspects of English law, and preparing and negotiating the transaction documentation. The U.S. team advised in regards to all aspects of US law, including the pre-IPO structuring of the company.
The cross-border team from Reed Smith’s Global Corporate Group and Financial Industry Group included partners James Wilkinson, Herb Kozlov, Wendy Grasso, Elizabeth Tabas-Carson, and Kevin Kay; counsel Trish O’Donnell, associates Fiona McFarlane, Kat McGriskin, Sheran Sharafi, and Rob Stalzer; trainee solicitor Victoria Lebed, and summer associate Selina Cook.
James Wilkinson said: “We are delighted to have supported Spectral MD on the placing and AIM listing. It was highly rewarding to collaborate across our tax, capital markets and regulatory teams to successfully advise on the transaction and enhance Spectral MD’s plan to bring their important technology to market.”
About Reed Smith
Reed Smith is a dynamic international law firm dedicated to helping clients move their businesses forward. With an inclusive culture and innovative mindset, we deliver smarter, more creative legal services that drive better outcomes for our clients. Our deep industry knowledge, long-standing relationships and collaborative structure make us the go-to partner for complex disputes, transactions, and regulatory matters. Now celebrating more than 140 years of service, our firm spans 30 offices with 3,000 people, including 1,700 lawyers.
For more information, please visit www.reedsmith.com.
